ECOR vs. ELMD, PROF, LAKE, INGN, DRTS, AVR, BWAY, SKIN, OBIO, and TLSI
Should you be buying electroCore stock or one of its competitors? The main competitors of electroCore include Electromed (ELMD), Profound Medical (PROF), Lakeland Industries (LAKE), Inogen (INGN), Alpha Tau Medical (DRTS), Anteris Technologies Global (AVR), BrainsWay (BWAY), Beauty Health (SKIN), Orchestra BioMed (OBIO), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.
electroCore vs.
electroCore (NASDAQ:ECOR) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
Electromed has a net margin of 11.34% compared to electroCore's net margin of -54.40%. Electromed's return on equity of 15.71% beat electroCore's return on equity.
Electromed has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
electroCore received 145 more outperform votes than Electromed when rated by MarketBeat users. However, 91.67% of users gave Electromed an outperform vote while only 62.55% of users gave electroCore an outperform vote.
electroCore has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
26.7% of electroCore shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 19.7% of electroCore shares are held by company insiders. Comparatively, 14.0% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
electroCore presently has a consensus target price of $25.50, indicating a potential upside of 278.56%. Electromed has a consensus target price of $38.00, indicating a potential upside of 59.80%. Given electroCore's higher possible upside, research analysts plainly believe electroCore is more favorable than Electromed.
In the previous week, electroCore had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for electroCore and 2 mentions for Electromed. Electromed's average media sentiment score of 1.01 beat electroCore's score of 0.43 indicating that Electromed is being referred to more favorably in the news media.
Summary
Electromed beats electroCore on 14 of the 19 factors compared between the two stocks.
Get electroCore News Delivered to You Automatically
Sign up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
electroCore Competitors List
Related Companies and Tools
This page (NASDAQ:ECOR) was last updated on 3/31/2025 by MarketBeat.com Staff